NCT04150393View on ClinicalTrials.gov

Safety and Tolerability Evaluation of MaaT033

PHASE1CompletedINTERVENTIONAL

Enrollment

21

Participants

Timeline

Start Date

October 20, 2020

Primary Completion Date

December 13, 2021

Study Completion Date

December 13, 2021

Conditions

Hematologic DiseasesChemotherapy Effect

Interventions

DRUG

MaaT033 capsule

Oral capsule

Trial Locations (4)

Unknown

CHU Angers, Angers

CHU Nice, Nice

APHP St Antoine, Paris

IUCT, Toulouse

Sponsors

Lead Sponsor

All Listed Sponsors

lead

MaaT Pharma

INDUSTRY